articleNew England Journal of MedicineOct 30, 2008BRONZE OA

Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety

Johns Hopkins University · Behavioral Pharma (United States) · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

Anxiety disorders are common psychiatric conditions affecting children and adolescents. Although cognitive behavioral therapy and selective serotonin-reuptake inhibitors have shown efficacy in treating these disorders, little is known about their relative or combined efficacy.

Methods

In this randomized, controlled trial, we assigned 488 children between the ages of 7 and 17 years who had a primary diagnosis of separation anxiety disorder, generalized anxiety disorder, or social phobia to receive 14 sessions of cognitive behavioral therapy, sertraline (at a dose of up to 200 mg per day), a combination of sertraline and cognitive behavioral therapy, or a placebo drug for 12 weeks in a 2:2:2:1 ratio. We administered categorical and dimensional ratings of anxiety severity and impairment at baseline and at weeks 4, 8, and 12.

Citation impact

1,435
total citations
FWCI
76.28
Percentile
100%
References
33
Citations per year

Authors

13

Topics & keywords

Keywords
  • Sertraline
  • Placebo
  • Medicine
  • Cognitive behavioral therapy
  • Anxiety
  • Clinical Global Impression
  • Psychiatry
  • Randomized controlled trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.